common.study.topics.clinical

Stereotactic Body Radiation Therapy for Breast Cancer

common.study.values.description

Stereotactic Body Radiation Therapy for Breast Cancer

This is a prospective, single institution, phase I-II study of stereotactic body radiotherapy (SBRT) for unresected breast cancer. Twenty-four patients with advanced breast cancer who are not candidates for surgery (metastatic disease, unresectable, medically inoperable) or decline surgery will be enrolled in a prospective study using SBRT (4 fractions of radiation therapy over 12-15 days) as the primary treatment modality.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Radiation - SBRT

Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase I-II Study of Stereotactic Body Radiation Therapy for Breast Cancer (SBRT Breast)

common.study.values.clinical-trial-id

NCT03585621

participant.views.study.view.id

e0RRLb